Exact Sciences Revolutionizes Colorectal Cancer Screening with the Launch of Cologuard Plus
Madison, WI – Exact Sciences Corp., a leading provider of diagnostic tests, recently announced the launch of Cologuard Plus, an advanced colorectal cancer screening test. This new innovation builds upon the success of the original Cologuard test, which has already helped thousands of individuals detect colorectal cancer early.
What is Cologuard Plus?
Cologuard Plus is an at-home, non-invasive screening test designed to detect colorectal cancer and precancerous polyps. The test analyzes DNA from stool samples, looking for abnormalities that could indicate the presence of colorectal cancer or adenomas, the most common type of precancerous polyp. With Cologuard Plus, patients receive a more comprehensive screening, as it also identifies certain molecular biomarkers associated with Lynch Syndrome, a hereditary condition that increases the risk of colorectal and other cancers.
How Does Cologuard Plus Differ from the Original Cologuard Test?
Cologuard Plus offers several improvements over its predecessor. The test’s expanded capabilities allow for the early detection of Lynch Syndrome, providing patients with essential information about their risk for colorectal cancer. Additionally, Cologuard Plus includes a patient support program, offering resources and guidance throughout the screening process.
Impact on Individuals
The launch of Cologuard Plus signifies a significant step forward in colorectal cancer screening. For individuals at average risk, this test offers a convenient, non-invasive, and comprehensive option for detecting colorectal cancer and precancerous polyps. For those with a family history or personal history of Lynch Syndrome, Cologuard Plus serves as an essential tool for earlier detection and potential prevention.
Impact on the World
Cologuard Plus has the potential to transform the landscape of colorectal cancer screening. By offering a more comprehensive test with expanded capabilities, Exact Sciences aims to increase early detection rates and reduce the number of colorectal cancer cases. Moreover, the test’s convenience and non-invasive nature may encourage more individuals to undergo regular screenings, ultimately saving lives and reducing healthcare costs associated with late-stage diagnoses and treatments.
Conclusion
The launch of Cologuard Plus marks a pivotal moment in colorectal cancer screening. This innovative test offers individuals a more comprehensive, convenient, and non-invasive option for detecting colorectal cancer and precancerous polyps. Furthermore, the test’s ability to identify Lynch Syndrome biomarkers enables earlier detection and potential prevention for those at increased risk. The world stands to benefit from Cologuard Plus, as increased early detection rates, reduced healthcare costs, and improved overall patient outcomes become a reality.
- Exact Sciences Corp. launches Cologuard Plus, an advanced colorectal cancer screening test
- Test analyzes DNA from stool samples for colorectal cancer and precancerous polyps
- Expanded capabilities include detection of Lynch Syndrome biomarkers
- Non-invasive, convenient option for individuals at average risk
- Essential tool for those with a family history or personal history of Lynch Syndrome
- Potential to increase early detection rates and reduce healthcare costs
